Quartalsbericht
Carmignac Portfolio Grandchildren: Letter from the Fund Manager
-
-12.3%Carmignac Portfolio Grandchildren performance
in the 2nd quarter of 2022 for the A EUR Acc share class
-
-10.8%Reference indicator’s performance
in the 2nd quarter of 2022
-
+38.2%Performance of the Fund
since launch1 versus +39.2% for the reference indicator
During the second quarter of 2022, Carmignac Portfolio Grandchildren (A EUR Acc share class) declined -12.3%, providing a return below its reference indicator which fell -10.8% over the same period.
Global Markets
In the second quarter, little has changed, and global markets continued to reflect the themes that drove returns in the previous three months of the year. More precisely, concerns over rising interest rates led to persistent downward pressure on the valuations of relatively highly rated stocks despite the underlying quality of such companies. This dynamic was exacerbated, as the quarter proceeded, by growing concerns over the impact of rising interest rates and the energy crisis on both future economic and corporate profit growth.
Portfolio Management
As a result, Technology and Industrial stocks – where we have high weightings – continued to be under pressure and, despite our Consumer Staples and Healthcare names holding up well, this backdrop led to the Fund lagging its reference indicator in the period.
Among the weakest names were Semiconductor leaders Nvidia and ASML. While Nvidia delivered solid fiscal Q1 results, they expect consumer related demand for their graphics chips (GPUs) to be impacted in the second quarter due to Chinese lockdowns and the Ukrainian war. Looking far ahead, we remain positive about the prospects of its leading technology exposure to megatrends such as datacentre’s growth and artificial intelligence. It’s the same long-term horizon for ASML, a name which recently we have slowly been adding to. The company, in fact, has a dominant position in lithography within the semiconductor manufacturing chain and has a large order backlog for their machines driven by increased penetration of the latest cutting edge EUV technology, both factors substantiating our investment thesis.
In the period, Kingspan had the worst performance among our Industrial names. While delivering a strong Q1 report, the insulation material company announced recent declines in order activity. Contrary to what we usually do when there is weakness in a name for which we have strong conviction, we have not taken the opportunity to increase exposure here. It is true that we remain committed to Kingspan on the back of better building insulation standards and regulation, and the widespread desire for energy efficient buildings but, the Fund’s macroeconomic overlay – a unique characteristic of the strategy – has guided us to reduce cyclicality in recent months. Furthermore, we have sold other more cyclical names such as Netflix, PayPal, and Walt Disney, but added holdings among the Consumer Staples such as Colgate-Palmolive and Procter & Gamble. This area of the market is characterised by resilient demand as consumers redirect spending to essentials in difficult economic environments. Additionally, on the back of the companies’ strength and desirability of brands, they are in good position to pass on to consumers cost increases of raw materials.
On the positive side, most of our names have delivered resilient fundamental results up to now. Examples include core stalwarts like Microsoft, Palo Alto and Intuit. The latter even increased full year guidance driven by their core small business accounting software suite.
Our Healthcare stocks have seen mixed fortunes recently. On the one side, Novo Nordisk continues to rise driven by accelerating demand for its diabetes and obesity drugs, Thermo Fisher has been rewarded on the back of its relative stability and visibility of core revenue, and Elevance Health (formerly known as Anthem), the US healthcare medical insurance company, gained value thanks to announced costs control measures. On the negative side, Intuitive Surgical and Stryker fell due to concerns over the strength of future hospital spending, as well as supply chain constraints. Align Technology (owner of the Invisalign brand) significantly fell on the slowing down of growth expectations. Nevertheless, we remain committed to these names and have added to them.
Further name of note is EA Sports, one of the better contributors in Q1 which we sold on strength as we see its industry vulnerable in a downturn. Conversely, we added ServiceNow – a player in the software sector – on weakness, as we are optimistic on the sustainability of the growth of their automated workflow management tool which has become an essential corporate application post-pandemic
Outlook
Other than the above-mentioned changes, activity has been contained. As one would expect from an investment process that focuses entirely on businesses that have proven ability to sustain high levels of profitability, most of our holdings have not disappointed to date. Our focus remains on identifying and owning profitable companies with high return on capital. These companies, we believe, are in a good position to deliver results over a five year or longer time horizon.
Source: Company website, Bloomberg, Carmignac, June 2022 1: 31/05/2019
Carmignac Portfolio Grandchildren A EUR Acc
Empfohlene Mindestanlagedauer
Geringstes Risiko Höchstes Risiko
AKTIENRISIKO: Änderungen des Preises von Aktien können sich auf die Performance des Fonds auswirken, deren Umfang von externen Faktoren, Handelsvolumen sowie der Marktkapitalisierung abhängt.
WÄHRUNGSRISIKO: Das Währungsrisiko ist mit dem Engagement in einer Währung verbunden, die nicht die Bewertungswährung des Fonds ist.
RISIKO IN VERBINDUNG MIT DER VERWALTUNG MIT ERMESSENSSPIELRAUM: Die von der Verwaltungsgesellschaft vorweggenommene Entwicklung der Finanzmärkte wirkt sich direkt auf die Performance des Fonds aus, die von den ausgewählten Titeln abhängt.
Der Fonds ist mit einem Kapitalverlustrisiko verbunden.
Carmignac Portfolio Grandchildren A EUR Acc
2019 | 2020 | 2021 | 2022 | 2023 |
2024 (YTD) ? Year to date |
|
---|---|---|---|---|---|---|
Carmignac Portfolio Grandchildren A EUR Acc | +15.47 % | +20.28 % | +28.38 % | -24.16 % | +23.04 % | +20.01 % |
Referenzindikator | +15.49 % | +6.33 % | +31.07 % | -12.78 % | +19.60 % | +16.48 % |
Srollen Sie nach rechts, um die ganze Tabelle zu sehen
3 Jahre | 5 Jahre | 10 Jahre | |
---|---|---|---|
Carmignac Portfolio Grandchildren A EUR Acc | +5.49 % | +12.99 % | - |
Referenzindikator | +9.22 % | +12.98 % | - |
Srollen Sie nach rechts, um die ganze Tabelle zu sehen
Quelle: Carmignac am 30/08/2024
Einstiegskosten : | 4,00% des Betrags, den Sie beim Einstieg in diese Anlage zahlen. Dies ist der Höchstbetrag, der Ihnen berechnet wird. Carmignac Gestion erhebt keine Eintrittsgebühr. Die Person, die Ihnen das Produkt verkauft, teilt Ihnen die tatsächliche Gebühr mit. |
Ausstiegskosten : | Wir berechnen keine Ausstiegsgebühr für dieses Produkt. |
Verwaltungsgebühren und sonstige Verwaltungs- oder Betriebskosten : | 1,70% des Werts Ihrer Anlage pro Jahr. Hierbei handelt es sich um eine Schätzung auf der Grundlage der tatsächlichen Kosten des letzten Jahres. |
Erfolgsgebühren : | 20,00% wenn die Anteilsklasse während des Performancezeitraums den Referenzindikator übertrifft. Sie ist auch dann zahlbar, wenn die Anteilsklasse den Referenzindikator übertroffen, aber eine negative Performance verzeichnet hat. Minderleistung wird für 5 Jahre zurückgefordert. Der tatsächliche Betrag hängt davon ab, wie gut sich Ihre Investition entwickelt. Die obige aggregierte Kostenschätzung enthält den Durchschnitt der letzten 5 Jahre oder seit der Produkterstellung, wenn es weniger als 5 Jahre sind. |
Transaktionskosten : | 0,26% des Werts Ihrer Anlage pro Jahr. Hierbei handelt es sich um eine Schätzung der Kosten, die anfallen, wenn wir die Basiswerte für das Produkt kaufen oder verkaufen. Der tatsächliche Betrag hängt davon ab, wie viel wir kaufen und verkaufen. |